Table 5 Treatment response and complications of intermediate-stage HCC patients who underwent TACE, stratified by the ALBI-TAE model
Post-TACE evaluations | Group A | Group B | Group C | Group D | P value |
|---|---|---|---|---|---|
(n = 44) | (n = 216) | (n = 164) | (n = 56) | ||
mRECIST | < 0.001 | ||||
CR | 11 (25) | 48 (22) | 14 (9) | 1 (2) | |
PR | 26 (59) | 103 (48) | 57 (35) | 9 (16) | |
SD | 6 (14) | 40 (18) | 50 (30) | 22 (39) | |
PD | 1 (2) | 25 (12) | 43 (26) | 24 (43) | |
Treatment response | < 0.001 | ||||
Good response (CR + PR) | 37 (84) | 151 (70) | 71 (43) | 10 (18) | |
Poor response (SD + PD) | 7 (16) | 65 (30) | 93 (57) | 46 (82) | |
Complications | |||||
Post embolization syndrome | 5 (11) | 40 (18) | 51 (31) | 33 (59) | < 0.001 |
Liver decompensation | 0 (0) | 11 (5) | 15 (9) | 16 (29) | < 0.001 |